Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia switching in RA TNF-alpha secondary non-responders
NCT01147341Phase 4Completed
- Sponsor
- Michael Schiff
- Start
- Jul 2010
- Primary completion
- Jan 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 4 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Michael Schiff. Started Jul 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01147341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147341.